Zhang F, Dou Z, Ma Y, et al. Effect of earlier initiation of antiretroviral treatment and increased treatment coverage on HIV-related mortality in China: a national observational cohort study

Division of Treatment and Care, National Centre for AIDS/STD Control and Prevention, Chinese Centre for Disease Control and Prevention, Beijing, China.
The Lancet Infectious Diseases (Impact Factor: 22.43). 07/2011; 11(7):516-24. DOI: 10.1016/S1473-3099(11)70097-4
Source: PubMed


Overall HIV mortality rates in China have not been reported. In this analysis we assess overall mortality in treatment-eligible adults with HIV and attempt to identify risk factors for HIV-related mortality.
We used data from the national HIV epidemiology and treatment databases to identify individuals aged 15 years or older with HIV who were eligible for highly active antiretroviral therapy between 1985 and 2009. Mortality rates were calculated in terms of person-years, with risk factors determined by Cox proportional hazard regression. Treatment coverage was calculated as the proportion of time that patients who were eligible for treatment received treatment, with risk factors for not receiving treatment identified by use of logistic regression.
Of 323,252 people reported as having HIV in China by the end of 2009, 145,484 (45%) were identified as treatment-eligible and included in this analysis. Median CD4 count was 201 cells per μL (IQR 71-315) at HIV diagnosis and 194 cells per μL (73-293) when first declared eligible for treatment. Overall mortality decreased from 39·3 per 100 person-years in 2002 to 14·2 per 100 person-years in 2009, with treatment coverage concomitantly increasing from almost zero to 63·4%. By 2009, mortality was higher and treatment coverage lower in injecting drug users (15·9 deaths per 100 person-years; 42·7% coverage) and those infected sexually (17·5 deaths per 100 person-years; 61·7% coverage), compared with those infected through plasma donation or blood transfusion (6·7 deaths per 100 person-years; 80·2% coverage). The two strongest risk factors for HIV-related mortality were not receiving highly active antiretroviral therapy (adjusted hazard ratio 4·35, 95% CI 4·10-4·62) and having a CD4 count of less than 50 cells per μL when first declared eligible for treatment (7·92, 7·33-8.57).
An urgent need exists for earlier HIV diagnosis and better access to treatment for injecting drug users and patients infected with HIV sexually, especially before they become severely immunosuppressed.
The National Centre for AIDS/STD Control and Prevention of the Chinese Centre for Disease Control and Prevention.

Download full-text


Available from: Fujie Zhang,
  • Source
    • "A study indicated that the estimated mean age at death increased around 2–8 years over 1996–2007 in Latin American countries following the introduction of ART (Gonzalez et al., 2011). In China, the national free ART program was introduced in 2002 and the coverage of the free ART program expanded rapidly with 81,880 patients across the country had received free ART by the end of 2009 (Zhang, Pan, Yu, Wen, & Zhao, 2005; Zhang et al., 2011). It is possible that the national free ART program has extended survival of some patients with HIV/AIDS. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This study examined the time trend and pattern of HIV/AIDS-related deaths in China. Data on HIV deaths and AIDS deaths were provided by the Chinese Ministry of Health. Time trend of the overall death rates over the period 2000-2012 was examined using Poisson regression models. Pattern of AIDS deaths was examined for the period 2006-2012, using the age-, gender-, and region-specific death rates. The results indicated that HIV/AIDS-related death rate increased significantly in China over the past decade, with an average annual percentage change of 22.3%. A vast majority of the deaths occurred among those aged between 20 and 65 years, with two age peaks. The death rate was higher for males than females and in rural areas than urban areas. A total of 83% of the deaths occurred among rural residents and 67% among males. The upward trend and distribution pattern of HIV/AIDS-related deaths depicted in the present study not only provides valuable information for additional understanding of the dynamics of the HIV/AIDS epidemic in China, but also has implications for evidence-based public health intervention strategies and policies as well as for further studies.
    AIDS Care 01/2015; DOI:10.1080/09540121.2015.1005568 · 1.60 Impact Factor
  • Source
    • "Subsequently, PWID have a higher mortality than individuals infected through different modes (Zhang et al., 2011b). In view of such challenges, many investigators are seeking effective strategies to increase ART uptake and adherence in PWID populations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Using methadone maintenance therapy (MMT) clinics to deliver antiretroviral therapy (ART) is an effective strategy to promote treatment initiation and adherence for HIV-positive drug users. This paper describes the implementation barriers perceived by service providers for a study pilot designed to integrate ART services in MMT clinics. Methods The study was conducted in six MMT clinics in Sichuan province, China. Two service providers selected from each of the six clinics underwent training in administering ART. The trained providers delivered ART-related services in their clinics. A focus group was conducted among the service providers to assess their experiences and perceived challenges in delivering integrated services. Results Barriers at policy, institutional, provider, and client levels were identified. Policy level barriers included household registration restrictions and a lack of insurance coverage for testing expenses. Inefficient coordination between treatment sites and MMT clinics was an obstacle at the institutional level. Insufficient training and added workload were barriers at the provider level. Finally, conflict with daily dosing habits was identified as the primary reason that clients did not accept ART. Conclusions Although integrating ART into MMT clinics is beneficial, multilevel barriers to implementation need to be addressed. This study documents the need for treatment transferability and insurance coverage, protection of client confidentiality, proper provider training, coordination with treatment sites, and individualized ART service for MMT clients.
    The International journal on drug policy 07/2014; DOI:10.1016/j.drugpo.2014.04.021 · 2.54 Impact Factor
  • Source
    • "To understand the expanding HIV epidemic, the Chinese government took steps to scale up HIV screening to identify infected persons for early treatment in order to reduce the mortality and transmission242526. To better understand the trajectory of the HIV-1 epidemic in most-at-risk populations, China adopted the laboratory-based BED incidence assay initially developed at the U.S. CDC in 20025. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The HIV-1 BED incidence assay was adopted in China in 2005 for HIV-1 incidence surveillance. A proficiency testing (PT) program was established in 2006 to provide quality assurance services. The BED PT program consisted of two components, an international program provided by the U.S. Centers for Disease Control and Prevention from 2006 and a domestic program started by the National HIV/HCV Reference Laboratory in 2011. Each PT panel consisted of eight coded specimens distributed to participating laboratories semi-annually, and testing results were collected and analyzed. The number of participating laboratories increased progressively from 2006 to 2012. The Chinese HIV-1 incidence laboratory network performed satisfactorily both in international and domestic PT programs. We also demonstrated that the BED assay was highly reproducible among participating laboratories. Our success and lessons learned can be readily replicated in other countries or regions contemplating the establishment of a PT program for assay-based HIV incidence estimation.
    Scientific Reports 03/2014; 4:4512. DOI:10.1038/srep04512 · 5.58 Impact Factor
Show more